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Egypt has the highest prevalence of worldwide HCV (15%) and the highest prevalence of HCV-4, which is responsible for almost 90% 
of infections. There is increasing evidence that patients with different HCV genotypes have different clinical profiles, severity of 
liver disease and response to current combination therapy. HCV genotyping helps clinicians in their practice as it guides the selec-
tion of treatment regimens, and provides important epidemiological markers that enable outbreak source tracing and control of 
the spread of disease. 
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Background: At least six HCV (hepatitis C virus) genotypes are unequally distributed 
worldwide. HCV genotyping guides the selection of treatment regimens and provides 
important epidemiological markers that enable the outbreak source to be traced and 
the spread of disease to be controlled. In Egypt, there is an increasing need for cost-ef-
fective, fast, and easily performable HCV genotyping assays.Recently, a multiplex PCR 
assay was developed to determine HCV genotypes. It employs genotype-specific primers, 
based on sequences of the entire core region and part of the 5’UTR of the genome. 
Objectives: In this study, we compared a simple, new, modified multiplex PCR system for 
HCV genotyping with a commercially available line probe assay (INNO-LiPA) that is based 
on reverse hybridization.
Patients and Methods: Serum samples from chronic HCV Egyptian patients (n = 73) 
were genotyped using the modified multiplex PCR assay, and genotypes were verified 
using the INNO-LiPA HCV II assay.
Results: The modified multiplex PCR method was able to type HCV-4 in 65 of 70 typeable 
samples (92.86%) and had 100% concordance with the INNO-LiPA assay. 
Conclusions: Genotype 4 was the most prevalent genotype in our study. Based on our 
results, the modified multiplex nested PCR assay is a sensitive and inexpensive alterna-
tive for HCV genotyping and can be used in routine diagnostic laboratories. INNO-LiPA 
may be useful as a second-line assay for genotyping samples that are indeterminate by 
multiplex PCR. This approach will effect better treatment optimization and a reduction 
of the spread of HCV.  Copyright  c 2012 Kowsar Corp. All rights reserved. 
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1. Background
HCV genotype 4 (HCV-4) is responsible for more than 
80% of HCV infections in the Middle East and Africa and 
has recently spread to several European countries (1, 2). 
Egypt has one of the highest rates of HCV worldwide 
(~15%) and the highest prevalence of HCV-4, which is 
responsible for nearly 90% of all infections (1, 3, 4). Al-
though phylogenetic analysis of a coding region, or even 
the complete genome, is considered to be the gold stan-
dard for identifying HCV genotypes and subtypes (5), 
this approach is impractical for large-scale genotyping 
projects, since it is both expensive and time-consuming 
(6, 7). Thus, a variety of surrogate HCV typing procedures 
have been developed over the past 10 years, based pri-
marily on amplification of viral sequences by PCR. For 
all of these assays, only one region (eg, the 5’UTR, core) 
is analyzed as a representative of the entire genome (8-
13). Examples of such assays include those developed by 
Okamoto et al. and Ohno et al. (10, 11). One limitation of 
the assay by Okamoto et al. (1992) is that it was designed 
to detect genotypes 1, 2, and 3a (10). Thus, this system fails 
to type Egyptian strains, since no genotype 4-specific 
primers exist(14). Furthermore, the system also displays 
a higher number of mixed-infection designations, prob-
ably due to non-specific priming (11, 15).
A second example is the assay developed by Ohno et al. 
(1997) (11). However, it also needs to be revised or updated 
to enable new genotypesto be identified. In addition, 
the number of samples of genotypes 3, 4, 5, and 6 that 
were tested was very small and may not have been suffi-
cient to allow definitive conclusions to be drawn about 
this method. Moreover, the region that was used to de-
sign outer primers might not be suitable if all common 
subtypes are to be detected with great sensitivity (15). In 
an attempt to overcome this limitation and increase the 
sensitivity of the assay, Idrees (2008) developed an assay 
that amplifies a region from the 5’UTR, along with the 
entire core region, using genotype-specific primers (15). 
Since the primers were designed based on the nucleotide 
sequences of many genotypes/subgenotypes—namely, 1a, 
1b, 1c, 2a, 2b, 2c, 3a, 3b, 3c, 4a–h, 5a, and 6a HCV isolates—
this revised system has much broader applications. 
2. Objectives
The main goal of this study was to evaluate a modified 
multiplex PCR system, based on that described by Idrees 
(2008), for use as a reliable and economical HCV genotyp-
ing method for Egyptian patients and to compare the re-
sults of this system with those obtained using a commer-
cially available method that is based on the line probe 
assay, INNO-LiPA HCV II.
3. Materials and Methods
3.1. Materials
This study was conducted between January 2009 and 
October 2009 and included 100 anti-HCV-positive serum 
samples collected from patients who were chronically 
infected with HCV. Anti-HCV was tested using a third-
generation enzyme immunoassay (EIA) (Murex Anti-HCV 
(Version 4) ABBOTT Diagnostic Division, Murex Biotech 
S.A. (Pty) Ltd, Kyalami Boulevard, and Republic of South 
Africa). Samples were taken from the Biochemistry De-
partment of the Theodor Bilharz Research Institute and 
the Chemical Pathology Department of the Kasr Al-Aini 
Faculty of Medicine, Cairo University. The study was ap-
proved by the ethics committees from both hospitals. 
3.2. HCV RNA Extraction and PCR Detection
HCV RNA was extracted from 140 μL serum using the 
QIAamp Viral RNA Mini Kit (QIAgen, Hilden, Germany) 
and re-suspended in 60 µL buffer. Strict measures were 
taken throughout the sampling, extraction, and PCR to 
prevent nucleic acid carryover (16). Nested reverse-tran-
scription PCR (RT-PCR) was conducted, and HCV RNA-pos-
itive samples were genotyped.
3.3. HCV Genotyping Using a Modified Multiplex PCR 
Protocol
3.3.1. cDNA Synthesis and First-Round PCR Amplification
In this study, we modified the multiplex PCR protocol 
reported by Idrees (15). The RT and first-round PCR were 
performed in a single step. Briefly, cDNA synthesis and 
first-round PCR amplification were performed in a 50 μL 
reaction volume, containing 20 μL RNA, 50 pmol of each 
of the universal outer forward and reverse primers (Table 
1), 200 μM of each deoxynucleotide (dNTP), 10 U of avian 
myeloblastosis virus reverse transcriptase (AMV RT) (Pro-
mega Madison, WI, USA), 2.5 U of Taq DNA polymerase 
(Promega Madison, WI, USA), 40 U of RNAsin (Promega 
Madison, WI, USA), 20 mM Tris-HCl (pH 8.4), and 50 mM 
KCl. Reactions were performed in a PTC 200 thermal cy-
cler (MJ Research, Watertown, Mass., USA), programmed 
as follows:42°C for 30 min; 95°C for 5 min; 40 cycles of 
94°C for 1 min, 45°C for 1 min, and 72°C for 1 minute; and 
72°C for 5 min. This process amplified a 470 bp band, 
which comprised part of the 5’UTR and the entire core 
region. 
3.3.2. Second-Round PCR 
Second-Round PCR was performed as in Idrees (15), in 
which 2 parallel second-round PCR reactions (20 μL each) 
were conducted for each sample, using the first-round 
PCR amplicon and primer mixes A or B. Table 1 summa-
rizes the universal and genotype-specific primers. Tubes 
were placed into a thermocycler that was programmed 
for 35 cycles as follows: 15 cycles (94°C, 50°C, and 72°C, for 
45 s, 45 s, and 1 min respectively); 20 cycles (94°C, 58°C, 
and 72°C, for 45 s, 45 s, and 1 min, respectively); and a 
final extension at 72°C for 10 min. Amplicons were then 
resolved by agarose gel electrophoresis (2.5%), yielding 267 Hepat Mon. 2012;12(4)
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genotype-specific band sizes, which were compared with 
a 50 bp DNA ladder. The choice of primer combinations 
(mixes  A  and  B)  was  decided,  based  on  differences  in 
genotype-specific band sizes. Figure 1 illustrates the mul-
tiplex PCR design. 
3.4. INNO-LiPA
All samples were also analyzed by VERSANT HCV Geno-
type assay (INNO-LiPA HCV II; Bayer Health Care, Eragny, 
France) per the manufacturer’s instructions (17). 
3.5. Statistical Analysis
Data were analyzed using the SPSS, release 17.0. Categor-
ical variables were expressed as rates (%). Correlation and 
kappa test of agreement between the two assays were 
performed. P values ≤ 0.05 were considered statistically 
significant.
4. Results
Of the 100 serum samples that tested positive for anti-
HCV, 73 (73%) specimens were found to be positive by RT-
PCR. There was a predominance of males among HCV 
RNA-positive patients: 58/73 (79.5%) males versus 15/73 
(20.5%) females. Out of 73 RNA-positive samples, 70 (96%) 
were successfully genotyped by the modified multiplex 
PCR system; the remaining 3 samples (4%) were nontype-
able (all male patients). Of the 70 typeable samples, 55 
(79%) were from male patients, while 15 (21%) were from 
female patients. Typeable samples were distributed 
as follows: 1 was genotype 1a (1.43%); 1 was genotype 1b 
(1.43%); 3 were genotype 3a (4.28%); and 65 were genotype 
4 (a-h) (92.86%). Figure 2 shows genotype-specific bands 
byagarose gel electrophoresis. By INNO-LiPA assay, 72/73 
(98.6%) samples were successfully genotyped: 57/72 (79%) 
were males versus 15/72 (21%) females. Only 1 of 73 (1.4%), 
a male patient, was non-typeable. Typeable samples had 
the following distribution: 1 was genotype 1a (1.4%); 1 was 
genotype 1b (1.4%); 3 were genotype 3a (4.2%); 38 were 
genotype 4 (52.8%); 2 (2.8%) were genotype 4a; 18 were 
genotype 4c/4d (24.9%); 5 were genotype 4e (6.9%); and 
4 were genotype 4h (5.6%). Figure 3 shows a sample of 
INNO-LiPA HCV II results. Based on a comparison of the 
results of both assays (Table 2), the genotypes of samples 
that were typeable by the modified multiplex PCR meth-
od were the same as those typed by the INNO-LiPA assay 
(100% concordance). Of the 3 samples that were not type-
able by the first assay, 2 were typeable by the second: 1  Figure 1. Schematic Design of the Modified Multiplex PCR Assay for HCV 
Genotyping
Figure 2. Agarose Gel Electrophoresis of the Modified Multiplex PCR Ge-
notyping Method Showing Genotype-Specific Bands
Lane 1 and 7: genotype 4 (288 bp); Lane 2: negative control; Lane 3: non-
typeable; Lane 4: genotype 1a (129 bp); Lane 5: genotype 1b (233 bp); Lane 
6: genotype 3a (258 bp); M: DNA ladder (50 bp)
Figure 3. HCV Genotyping Using the INNO-LiPA HCV II Assay System
Lane 1: reference; Lane 2: genotype 1a; Lane 3: genotype 1b; Lane 4: geno-
type 4a; Lane 5: genotype 4c/d; Lane 6: genotype 4e; Lane 7: genotype 4h; 
Lane 8: genotype 4268 Hepat Mon. 2012;12(4)
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was typed genotype 4 and the other was typed 4c/4d. The 
genotype of 1 sample was non-typeable by either assay. 
A significant positive correlation was observed between 
both methods (r = 0.874, P < 0.001). By kappa test, there 
was excellent agreement (kappa = 0.848) in the results 
between the two assays.
5. Discussion
There is increasing evidence that patients who are 
infected  with  different  HCV  genotypes  have  disparate 
clinical profiles, liver disease severities, and responses to 
current combination therapy. Hence, a convenient and 
reliable genotyping system is essential for large-scale 
epidemiological and clinical studies (18, 19). Although 
HCV-4 is the cause of approximately 20% of the 170 mil-
lion cases of chronic hepatitis C worldwide, it has not 
been the subject of significant research; thus, the fea-
tures of this genotype and management strategies for 
patients who have been infected with this genotype are 
not as well developed as for genotypes 1, 2, and 3 (20). 
HCV-4 is a very heterogeneous genotype that displays 
significant genetic divergence and more subtypes than 
other genotypes. To date, 18 subtypes have been identi-
fied (21, 22). However, the full clinical significance of HCV-
4 subtypes is not known, because few studies have been 
conducted on the correlation between HCV-4 subtypes 
and the natural history of the disease, pathogenicity, dis-
ease severity, and therapeutic outcomes (23, 24). In this 
study, HCV chronic hepatitis was more frequent in males 
PCR rounds Sequence a Specificity Polarity
RT & first PCR TTG TGG TAC TGC CTG ATA GGG Universal outer Sense
GGA TGT ACC CCA TGA GG(A) TCG Universal outer Anti-sense
Second PCR (Mix A) GTG CCC CGG GAG GTC TCG TAG Universal inner Sense
ACT CCA CCA ACG ATC TGA CC Type 1a  Anti-sense
AGC CTT GGG GAT AGG TTG TC Type 1b  Anti-sense
CTT ACC CAA ATT GCG TGA CC Type 1c  Anti-sense
ACT CCA CCA ACG ATC TGT CC Type 3a  Anti-sense
GTG ACC GCT CGG AAG TCT TA Type 3c  Anti-sense
CCG TAA AGA GGC CAT GGA TA Type 4  Anti-sense
Second PCR (Mix B) GTG CCC CGG GAG GTC TCG TAG Universal inner Sense
CTC CGA AGT CTT CCT TGT CG Type 2a  Anti-sense
AGC AAG TAA ACT CCG CCA AC Type 2b  Anti-sense
ACC GTT CGG AAG TTT TCC TC Type 2c  Anti-sense
AGC CTT GGG GAT AAG GTG AC Type 3b  Anti-sense
AAT CCG CAC GTT AGG GTA TG Type 5a  Anti-sense
CAG CCT TCG CTT CCA TAA AG Type 6a  Anti-sense
Table 1. Universal and Genotype Specific Primers Used for Modified Multiplex Nested PCR
a Nucleotide inside parentheses is a degenerate nucleotide
HCV Genotype Modified Multiplex PCR Method (Genotype Specific Primers) INNO-LiPA HCV II (Line Probe Assay)
Isolates, No. Percentage Isolates, No. Percentage
1a 1  1.37 1  1.37
1b 1  1.37 1  1.37
3a 3  4.11 3  4.11
4 65 89.04 38 52.05
4a - - 2  2.74
4c/4d - - 18 24.66
4e - - 5  6.85
4h - - 4  5.48
Not Genotyped 3  4.11 1  1.37
Total 73  100 73 100
Table 2. Comparison of Results Generated by Both Systems269 Hepat Mon. 2012;12(4)
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over females (3.9:1), confirming earlier reports (14, 25-
30). This observation may be related in part to social risk 
factors for HCV transmission, such as drug use, schisto-
somiases, and occupational exposure. However, the role 
of androgens in the gender bias must not be excluded 
(14). In this study, a novel modified multiplex nested 
PCR method was compared directly with a commercial 
INNO-LiPA assay method for HCV genotyping. Based on 
our results, the modified PCR method had a similar level 
of accuracy as the INNO-LiPA method but was simpler to 
use and significantly less expensive. In fact, all 70 type-
able genotypes obtained by the modified PCR method 
matched those obtained from the INNO-LiPA method 
(100% concordance). Two of the 3 samples that were non-
typeable by modified multiplex PCR method were type-
able by INNO-LiPA method: 1 was typed genotype 4, and 
the other was 4c/4d. The genotype of 1 sample was non-
typeable by either method, likely due to low viral load 
(r = 0.874, P < 0.001). More importantly, the modified 
multiplex PCR method was appropriate for typing the 
prevalent HCV strains in our patient population. In fact, 
the HCV genotype 4 was detected in 65 out of 70 patients 
(92.86%), supporting earlier studies (14, 31-36). However, 
our data also show that the contribution of genotype 4 to 
the study pool is not exclusive and that other genetically 
related genotypes exist in the population, confirming 
previous studies (14, 37, 38). One cansuggest a deficiency 
of the multiplex PCR in subtyping genotype 4, but inclu-
sion of more primers would be an unjustified burden on 
an already financially challenged health care system, in 
the absence of sufficient evidence to support clinical and 
therapeutic outcomes (23, 24).
One limitation of this multiplex method is the rar-
ity of HCV genotypes other than genotype 4 in Egypt. 
However, in the original work by Idrees, 2008, the most 
prevalent genotype in Pakistan (3a) was detected with 
high frequency. Lower frequencies of other genotypes 
(3b,1a,3c,1b,2a,4,1c) were also observed. He suggested that 
due to higher sensitivity of the method, it may be useful 
for detecting other genotypes in regions of the world 
where they are predominant to validate its suitability for 
these genotypes (eg, 5a and 6a) (15). In conclusion, geno-
type 4 was the most prevalent genotype in our study. 
Based on our results, the new, modified multiplex nested 
PCR assay that we have presented is a sensitive, inexpen-
sive alternative for HCV genotyping and is capable of reli-
ably genotyping HCV RNA directly from clinical samples; 
thus, this novel assay can be used in routine diagnostic 
laboratories. Furthermore, INNO-LiPA may be useful as a 
second-line assay for genotyping samples that are inde-
terminate by multiplex PCR. This combination will lead 
to better patient evaluation, better treatment optimi-
zation, and a reduction in the spread of HCV. Moreover, 
the use of both genotyping assays in Egyptian patients 
might be valuable for large-scale genotyping projects on 
a national level.
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